Loading
Life sciences · Journal article
BMC Cancer · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background c-ros oncogene 1 (ROS1) rearrangement is a rare yet significant genetic abnormality in non-small cell lung cancer. However, real-world treatment data for Non-Small Cell Lung Cancer (NSCLC) patients with different ROS1 fusion subtypes remain limited. Methods Medical records of 99 NSCLC patients with ROS1 rearrangement diagnosed at Beijing Chest Hospital from February 2017 to January 2025 were reviewed. Clinicopathological characteristics, treatment regimens, and efficacy were retrospectively collected, and factors influencing therapeutic outcomes were analyzed. Results A total of 55 patients were included in this study. CD74 was the most common fusion partner. Targeted therapy accounts for 87.3% of first-line treatment. All patients received targeted therapy during their treatment course. The objective response rate (ORR) for first-line treatment was 72.7%, with a median progression-free survival (PFS) of 18.9 months. SDC4 subtype group showed significantly lower ORR than non-SDC4 subtype group in first-line treatment (44.4% vs. 86.1%, P = 0.025). Patients with programmed death-ligand 1 (PD-L1) < 1% had remarkably longer median PFS compared to those with PD-L1 ≥ 1% (not reached vs. 17.3 months, P = 0.031). Univariate Cox regression analysis revealed that SDC4 subtype and baseline bone metastasis were associated with significantly shorter median PFS (7.5 months vs. 22.4 months, P = 0.026; 7.5 months vs. 24.2 months, P = 0.009, respectively). In addition, patients received first-line targeted therapy and those responded to first-line treatment showed noticeably longer median PFS (22.4 months vs. 6.4 months, P = 0.005; 23.6 months vs. 4.4 months, P < 0.001, respectively). Multivariate analysis revealed that SDC4 subtype, bone metastasis status, and the use of TKIs as first-line treatment were independent prognostic factors for PFS of first-line therapy. The median overall survival (OS) of the total patients was 59.8 months. Univariate Cox regression analysis showed that smoking history and baseline liver metastasis were associated with a remarkably shorter median OS (22.6 months vs. 63.2 months, P = 0.018; and 23.8 months vs. 63.2 months, P = 0.013, respectively), while response to the initial targeted therapy was related to significantly longer median OS (59.8 months vs. 22.6 months, P = 0.043). Conclusions Patients with advanced ROS1-rearranged NSCLC benefit from targeted therapy. SDC4 subtype, PD-L1 expression level and baseline metastasis status affects efficacy and survival.